Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730466 | 0.81 | HTT (0.36) | HTT | |
| SCHEMBL4812433 | 0.81 | HTT (0.32) | HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13280244 | 0.76 | HTT (0.37) | HTT | |
| SCHEMBL939429 | 0.73 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL974718 | 0.72 | HTT (0.50) | HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31729547 | 0.68 | HTT (0.34) | HTT | |
| SCHEMBL8707556 | 0.68 | ALDH1A1 (0.35) | — | |
| SCHEMBL28340713 | 0.68 | HTT (0.34) | HTT | |
| SCHEMBL1563399 | 0.66 | TSHR (0.55) | — | |
| SCHEMBL9936931 | 0.64 | NAAA (0.44) | HTTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351726-B2 | Substituted oxadiazolidinediones | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1663213-A1 | SUBSTITUTED OXADIAZOLIDINEDIONES AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030204-A1 | SUBSTITUTED OXADIAZOLIDINEDIONES AS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070585-A1 | Substituted oxadiazolidinediones | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070585-A1 | Substituted oxadiazolidinediones | OXA1L, COXFA4L2, DPYD | HTT 2980/4885NPC1 3007/4885RAB9A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.